Pfizer Puts $6M Down On Rights To Stem Cell Therapy
Pfizer Inc. has agreed to pay $6 million in cash, with a promise of up to $105 million more, for the rights to an investigational stem cell therapy used to treat...To view the full article, register now.
Already a subscriber? Click here to view full article